| Chemical Name | (R)-(-)-3-Quinuclidinol |
| Synonyms | (R)-3-Quinuclinol; Solifenacin Succinate Intermediate C |
| CAS Number | 25333-42-0 |
| CAT Number | RF-CC117 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C7H13NO |
| Molecular Weight | 127.18 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Off-White Powder |
| Identification RT (by GC) | Conform with the Reference Standard |
| Melting Point | 212.0~224.0℃ |
| Specific Rotation [α]D20 | -40.0°~ -48.0° |
| Moisture (K.F) | ≤0.5% |
| Residue on Ignition | ≤0.5% |
| Purity | ≥99.0% |
| Total Impurities | ≤1.0% |
| Chiral Purity | ≥99.0% |
| Enantiomer | ≤1.0% |
| Assay | 98.0%～101.0%（on anhydrous basis） |
| Test Standard | Enterprise Standard |
| Usage | Chiral Compounds; Pharmaceutical Intermediates |
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (R)-(-)-3-Quinuclidinol (CAS: 25333-42-0) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and Active Pharmaceutical Ingredient (API) synthesis.
(R)-(-)-3-Quinuclidinol (CAS: 25333-42-0) can be used as an intermediate in the synthesis of Solifenacin Succinate (CAS: 242478-38-2)
Solifenacin Succinate (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence.
Solifenacin Succinate (CAS: 242478-38-2) is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. Solifenacin displays affinity for both M3 and M2 receptors with Ki values of 9.9nM and 120 nM, respectively. Since muscarinic salivary glands are of the M3 persuasion, a common side effect of antimuscarinic therapy is dry mouth. At the cellular level, solifenacin possesses a selective preference for bladder over salivary gland that is 15-fold greater than that of atropine suggesting a lower probability of inducing dry mouth at pharmacologically relevant doses. The synthesis of solifenacin involves the preparation of racemic 1-phenyl- 1,2,3,4-tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-phenyl-1,2,3,4-tetrahydroisoquinoline may be subjected to optical resolution with (+)-tartaric acid prior to treatment with ethyl chloroformate and subsequent transesterification.